Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The pyruvate dehydrogenase E1 component is a key enzyme within the pyruvate dehydrogenase complex (PDC), which catalyzes the oxidative decarboxylation of pyruvate to acetyl-CoA and CO₂. This reaction is crucial for linking glycolysis to the citric acid (Krebs) cycle, enabling cells to convert carbohydrates into usable energy in the form of ATP. The E1 enzyme is a heterotetramer composed of two alpha (α) and two beta (β) subunits. The primary function of E1 is to catalyze the decarboxylation of pyruvate to produce CO₂ and a hydroxyethyl intermediate bound to thiamine diphosphate (ThDP/TPP), and the transfer of this hydroxyethyl group from ThDP/TPP on E1 to lipoamide on the E2 component, forming acetyl-dihydrolipoamide-E2. By converting pyruvate into acetyl-CoA, PDC enables entry into mitochondrial metabolism for ATP production. Activity can be regulated through phosphorylation/dephosphorylation mechanisms. Mutations in the gene encoding the alpha subunit (PDHA1) can cause metabolic disorders such as lactic acidosis.
Inhibition of enzymatic activity of E1 subunit in the pyruvate dehydrogenase complex.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pyruvate Dehydrogenase E1 Component.